

Bringing extended release to life.

NEW  
**apriso**  
 (mesalamine) 0.375g  
 EXTENDED-RELEASE CAPSULES


Bringing INTELLICOR™ delivery to UC

Delayed- and extended-release delivery for 24-hour protection<sup>1</sup>




1

- The delayed-release coating on each granule dissolves at a pH  $\geq$  6, a level frequently achieved in the gastrointestinal (GI) tract<sup>2</sup>



2

- The extended-release polymer matrix core swells, gradually distributing mesalamine throughout the colon<sup>1</sup>



3

- A once-daily dose releases thousands of granules, providing a greater surface area from which to release mesalamine<sup>1</sup>



To order, please contact your Wholesaler or Warehousing Chain.

ORDER INFORMATION	
NDC NUMBER	UNIT SIZE
65649-103-02	120 ct. bottle

WHOLESALER	ITEM NUMBER
AmerisourceBergen	262-626
Bellco Drug Corp.	301760
Cardinal	4141412
CVS	695008
H.D. Smith/Barnes	2219186
Kinray	329060
Morris & Dickson	948745
McKesson	3215423
Mutual Wholesale Drug	706903
Peytons Kroger Stores	3624996
Peytons Non-Kroger Stores	281279
Prescription Supply, Inc.	551440
Quality King Distributors	78876
Rite Aid	602798
Walgreens	499935

APRISO is a locally acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis in patients 18 years and older.

APRISO is contraindicated in patients with hypersensitivity to salicylates, aminosalicylates, or to any of the components of APRISO capsules.

The recommended dose of APRISO is four 0.375-g capsules once daily in the morning (1.5 g/day) with or without food. Because dissolution of the coating of APRISO granules depends on pH, APRISO should not be coadministered with antacids. Patients with phenylketonuria should be aware that APRISO contains aspartame, equivalent to 0.56 mg of phenylalanine.

In 2 well-controlled clinical trials, the most common treatment-related adverse events occurring in at least 3% of adult patients taking 1.5 g/day of APRISO were headache (11% vs 8% for placebo), diarrhea (8% vs 7% for placebo), upper abdominal pain (5% vs 3% for placebo), nausea (4% vs 3% for placebo), nasopharyngitis (4% vs 3% for placebo), influenza and influenza-like illness (4% vs 4% for placebo), and sinusitis (3% vs 3% for placebo).

Complete prescribing information for APRISO is available at [www.salix.com](http://www.salix.com)

**References:** 1. APRISO [prescribing information]. Morrisville, NC: Salix Pharmaceuticals, Inc.; 2008. 2. Fallingborg, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen HH. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. *Aliment Pharmacol Ther.* 1989;3:605-613. Salix Pharmaceuticals, Inc. 3. Safdi A, Pieniazek H, Crigston A, Forbes W. Multiple-dose pharmacokinetics of granulated mesalamine, a unique formulation providing delayed and extended release of 5-ASA. Poster presented at: American College of Gastroenterology Annual Scientific Meeting; October 3-8, 2008; Orlando, FL. 4. Data on file. Salix Pharmaceuticals, Inc.



APRISO™ and INTELLICOR™ are trademarks of Salix Pharmaceuticals, Inc.  
 ©2009 Salix Pharmaceuticals, Inc. All rights reserved. MCOGM 08/07a

For patients seeking reimbursement support, please call 1.800.444.DRUG (1.800.444.3784).

For more information, please visit [www.apriso-uc.com](http://www.apriso-uc.com).



Pharmacist Flash is a division of PDQ Communications • Communicating Healthcare Information in a Flash

APRISO is a locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis in patients 18 years and older.  
 APRISO is contraindicated in patients with hypersensitivity to salicylates, aminosalicylates, or to any of the components of APRISO capsules.  
 The recommended dose of APRISO is four 0.375 g capsules once daily in the morning (1.5 g/day) with or without food. Because dissolution of the coating of APRISO granules depends on pH, APRISO should not be coadministered with antacids.